- Just-Evotec Biologics expands its development and manufacturing agreement with ABL.
- The collaboration focuses on the production of broadly neutralising antibodies against HIV.
Just-Evotec Biologics, a Contract Development and Manufacturing Organisation (CDMO), has announced an expansion of its development and manufacturing agreement with ABL. The partnership is set to enhance the production of broadly neutralising antibodies against HIV, marking a significant stride in the battle against the global epidemic.
The expanded agreement will see Evotec Biologics and ABL working closely to optimise the production of these crucial antibodies. This collaboration is expected to accelerate the availability of these antibodies to patients in need, potentially transforming the landscape of HIV treatment and prevention.
Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to expand our long-standing partnership with ABL to include the development of a third bNAb. By leveraging Just – Evotec Biologics’ next-generation biomanufacturing platform we provide an integrated development and manufacturing solution for our partner to support the delivery of new therapeutic options targeting HIV together.”
Lauren Hudacik, President and Chief Executive Officer at ABL, added: “ABL has a long history of supporting the U.S. government’s mission to develop effective prevention and therapeutic products against HIV. This expansion of partnership with Just – Evotec Biologics strengthens that tradition.”
Dr Linda Zuckerman, Executive Vice President Global Head Biotherapeutics at Just – Evotec Biologics stated: “Building from the long-standing collaboration in the development of broadly-neutralising antibodies against HIV, we are excited to leverage Just – Evotec Biologics’ intensified continuous bioprocessing infrastructure to drive ABL’s towards clinical validation.”
